# Sacituzumab Tirumotecan (Sac-TMT/SKB264) Plus Tagitanlimab (KL-A167) in Patients With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma and Gastric/Gastroesophageal Junction Adenocarcinoma

> **NCT07701681** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Sun Yat-sen University** · enrollment: 75 (estimated)

## Conditions studied

- ESCC
- Gastric Adenocarcinoma
- Gastroesophageal Junction Adenocarcinoma
- Esophageal Squamous Cell Carcinoma (ESCC)
- GC/GEJC

## Interventions

- **DRUG:** Sacituzumab Tirumotecan + Tagitanlimab

## Key facts

- **NCT ID:** NCT07701681
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-08-31
- **Primary completion:** 2028-09-01
- **Final completion:** 2029-09-01
- **Target enrollment:** 75 (ESTIMATED)
- **Last updated:** 2026-07-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07701681

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07701681, "Sacituzumab Tirumotecan (Sac-TMT/SKB264) Plus Tagitanlimab (KL-A167) in Patients With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma and Gastric/Gastroesophageal Junction Adenocarcinoma". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07701681. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*